A specific anti‐COVID‐19 BNT162b2 vaccine‐induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients

• Published in: Clinical & translational immunology Vol. 12; no. 3; pp. e1434 - n/a
• Main Authors: Severa, Martina, Rizzo, Fabiana, Sinigaglia, Alessandro, Ricci, Daniela, Etna, Marilena Paola, Cola, Gaia, Landi, Doriana, Buscarinu, Maria Chiara, Valdarchi, Catia, Ristori, Giovanni, Riccetti, Silvia, Piubelli, Chiara, Palmerini, Pierangela, Rosato, Antonio, Gobbi, Federico, Balducci, Stefano, Marfia, Girolama Alessandra, Salvetti, Marco, Barzon, Luisa, Coccia, Eliana Marina
• Format: Journal Article
• Language: English
• Published: Australia John Wiley & Sons, Inc 2023; John Wiley and Sons Inc; Wiley
• Subjects: Chemokines; Coronaviruses; COVID-19 vaccines; Cytokines; Gene expression; Genes; humoral response; Immune response; Immune response (humoral); Immunization; Immunology; Infections; Innate immunity; Interferon; Interferon regulatory factor 1; Interleukin 15; Interleukin 6; IP-10 protein; Ligands; Medical research; Monoclonal antibodies; Monocyte chemoattractant protein 1; mRNA vaccine; mRNA vaccines; Multiple sclerosis; Myxovirus resistance proteins; Original; Peripheral blood mononuclear cells; Proteins; SARS‐CoV‐2; Severe acute respiratory syndrome coronavirus 2; Spike glycoprotein; Tumor necrosis factor-TNF; Tumor necrosis factor-α; γ-Interferon; innate immunity; SARS‐CoV‐2; humoral response; mRNA vaccine

Objectives The very rapidly approved mRNA‐based vaccines against SARS‐CoV‐2 spike glycoprotein, including Pfizer‐BioNTech BNT162b2, are effective in protecting from severe coronavirus disease 2019 (COVID‐19) in immunocompetent population. However, establishing the duration and identifying correlates...